Longwood Fund

  • About
  • Portfolio
  • Team
  • Press
  • Investor Login
  • Industry Events
  • About
  • Portfolio
  • Team
  • Press
  • Investor Login
  • Industry Events

Solu Therapeutics Closes $41M Series A Financing and Announces First Patient Dosed in Phase 1 Clinical Trial of STX-0712 in Patients with CMML and Other Advanced Hematologic Malignancies

April 9, 2025

Rectify Pharma Announces Publication of BSEP Transporter Biophysical Characterization in Communications Biology

April 8, 2025

Newleos Therapeutics Expands Leadership Team to Advance its Clinical-Stage Neuropsychiatric Programs and Drive Corporate Growth

April 8, 2025

BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors

April 2, 2025

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219

March 21, 2025

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 12, 2025
« Older Entries
Newer Entries »

Longwood Fund

The Prudential Tower

800 Boylston Street
Suite 1715
Boston, MA, 02199

  • About
  • Portfolio
  • Team
  • Press
  • Investor Login
  • Industry Events

© Longwood Fund. All Rights Reserved